Drug-Linker Conjugates for ADC

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker that combines the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, to enhance its ability to target and kill cancer cells effectively.

7-O-(Cbz-N-amido-PEG4)-paclitaxel is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity. It achieves this through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB ADC linker.

AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate for antibody-drug conjugates (ADCs), featuring a natural bis-intercalator, SW-163D, attached through an AcLysValCitPABC-DMAE linker[1].

Gly3-VC-PAB-MMAE 由 ADC 连接体 Gly3-VC-PAB 和微管抑制剂 MMAE 组成的化合物，可用于合成抗体偶联活性分子。

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs).

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation.

DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.